title: [Regression of metastatic hepatic cancer from gastric cancer by polysaccharide K and UFT administration--a case report].
abstract: Various treatments for hepatic metastasis of gastric cancer have been attempted, but problems remain with respect to long-term effectiveness and recurrence. Case reports have indicated the tumor regression effect of polysaccharide K(PSK)combined with chemotherapy, and meta-analysis has shown that PSK combined with chemotherapy improves the prognosis compared to chemotherapy alone. However, marked improvement of disease following PSK administration is rarely reported. We report a case of hepatic metastasis of gastric cancer in which low-dose UFT and PSK therapy resulted in regression of metastatic hepatic lesions and improvement of tumor markers. A 78-year-old man had synchronous hepatic metastasis of gastric cancer. Gastrectomy and microwave coagulation therapy using Microtase were conducted, followed by postoperative adjuvant chemotherapy with UFT 300 mg/day. Recurrences of metastatic hepatic lesion and new hepatic lesion were observed 6 months after surgery. Addition of PSK to UFT chemotherapy was selected as the treatment for recurrences, resulting in disappearance of the hepatic lesions and normalization of tumor markers. The patient is alive without recurrence at this writing, 38 months after surgery.
authors.affiliation: Division of General and Gastroenterological Surgery, Dept. of Surgery(Omori), Toho University School of Medicine, Japan.
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Ohashi
authors.forename: Masashi
authors.initials: M
authors.lastname: Watanabe
authors.forename: Masami
authors.initials: M
authors.lastname: Ikeda
authors.forename: Tatsuki
authors.initials: T
authors.lastname: Nanami
authors.forename: Kunihiro
authors.initials: K
authors.lastname: Yamazaki
authors.forename: Satoshi
authors.initials: S
authors.lastname: Yajima
authors.forename: Youkou
authors.initials: Y
authors.lastname: Oshima
authors.forename: Teruaki
authors.initials: T
authors.lastname: Takeyama
authors.forename: Masao
authors.initials: M
authors.lastname: Ito
authors.forename: Fumi
authors.initials: F
authors.lastname: Saito
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood; D006801:Humans; D008113:Liver Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000556:secondary* / Q000601:surgery; D008297:Male; D011134:Polysaccharides / Q000627:therapeutic use*; D013274:Stomach Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology* / Q000601:surgery; D005641:Tegafur / Q000008:administration & dosage / Q000627:therapeutic use; D014057:Tomography, X-Ray Computed; D014498:Uracil / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D014408:Biomarkers, Tumor; D011134:Polysaccharides; D005641:Tegafur; D014498:Uracil